Abstract
Omeprazole (CAS 73590-58-6), an H+, K+ ATPase inhibitor, is a potent suppressor of gastric acid secretion and a very active substance in the treatment of duodenal and gastric ulcers. The kinetic profile of omeprazole is well defined for healthy volunteers and for some high-risk populations, but not so far for patients with liver disease. As the substance is mainly metabolized in the liver, changes in liver circulation and/or function might lead to changes in the pharmacokinetics of omeprazole. Aim of the study was to evaluate the kinetic profile in patients with liver disease and compare the results obtained in healthy volunteers. 16 subjects were included in the study: 8 patients with liver cirrhosis and 8 healthy volunteers. A single oral dose of omeprazole 20 mg was administered: plasma samples were collected for 24 h since omeprazole administration. The principal pharmacokinetic parameters were estimated for the two studied populations.
| Original language | English |
|---|---|
| Pages (from-to) | 420-422 |
| Number of pages | 3 |
| Journal | Arzneimittel-Forschung/Drug Research |
| Volume | 41 |
| Issue number | 4 |
| Publication status | Published - 1991 |
Fingerprint
Keywords
- Antiulcer drugs
- CAS 73590-58-6
- Cirrhosis, hepatic
- Omeprazole, clinical pharmacokinetics
ASJC Scopus subject areas
- Chemistry(all)
- Organic Chemistry
- Drug Discovery
- Pharmacology
Cite this
Pharmacokinetics of omeprazole in cirrhotic patients. / Rinetti, M.; Regazzi, M. B.; Villani, P.; Tizzoni, M.; Sivelli, R.
In: Arzneimittel-Forschung/Drug Research, Vol. 41, No. 4, 1991, p. 420-422.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pharmacokinetics of omeprazole in cirrhotic patients
AU - Rinetti, M.
AU - Regazzi, M. B.
AU - Villani, P.
AU - Tizzoni, M.
AU - Sivelli, R.
PY - 1991
Y1 - 1991
N2 - Omeprazole (CAS 73590-58-6), an H+, K+ ATPase inhibitor, is a potent suppressor of gastric acid secretion and a very active substance in the treatment of duodenal and gastric ulcers. The kinetic profile of omeprazole is well defined for healthy volunteers and for some high-risk populations, but not so far for patients with liver disease. As the substance is mainly metabolized in the liver, changes in liver circulation and/or function might lead to changes in the pharmacokinetics of omeprazole. Aim of the study was to evaluate the kinetic profile in patients with liver disease and compare the results obtained in healthy volunteers. 16 subjects were included in the study: 8 patients with liver cirrhosis and 8 healthy volunteers. A single oral dose of omeprazole 20 mg was administered: plasma samples were collected for 24 h since omeprazole administration. The principal pharmacokinetic parameters were estimated for the two studied populations.
AB - Omeprazole (CAS 73590-58-6), an H+, K+ ATPase inhibitor, is a potent suppressor of gastric acid secretion and a very active substance in the treatment of duodenal and gastric ulcers. The kinetic profile of omeprazole is well defined for healthy volunteers and for some high-risk populations, but not so far for patients with liver disease. As the substance is mainly metabolized in the liver, changes in liver circulation and/or function might lead to changes in the pharmacokinetics of omeprazole. Aim of the study was to evaluate the kinetic profile in patients with liver disease and compare the results obtained in healthy volunteers. 16 subjects were included in the study: 8 patients with liver cirrhosis and 8 healthy volunteers. A single oral dose of omeprazole 20 mg was administered: plasma samples were collected for 24 h since omeprazole administration. The principal pharmacokinetic parameters were estimated for the two studied populations.
KW - Antiulcer drugs
KW - CAS 73590-58-6
KW - Cirrhosis, hepatic
KW - Omeprazole, clinical pharmacokinetics
UR - http://www.scopus.com/inward/record.url?scp=0025853739&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025853739&partnerID=8YFLogxK
M3 - Article
C2 - 1859516
AN - SCOPUS:0025853739
VL - 41
SP - 420
EP - 422
JO - Arzneimittel-Forschung/Drug Research
JF - Arzneimittel-Forschung/Drug Research
SN - 0004-4172
IS - 4
ER -